Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs Topotecan in 2nd Line SCLC
NCT01500720Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2012
- Primary completion
- Apr 2014
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in small cell lung cancer (SCLC), sponsored by Sanofi. Started Mar 2012; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01500720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500720.